Novakand Pharma AB (publ) (FRA:3EE0)

Germany flag Germany · Delayed Price · Currency is EUR
0.0001
0.00 (0.00%)
Last updated: Jan 20, 2026, 8:04 AM CET
-99.87%
Market Cap1.56M -86.7%
Revenue (ttm)n/a
Net Income-4.69M
EPS-0.04
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume613
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Range0.0001 - 0.1552
Betan/a
RSI48.02
Earnings DateFeb 20, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in Septembe... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 5
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3EE0
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements